Vas Narasimhan
Vas Narasimhan is the Chief Executive Officer of Novartis, a leading global healthcare company. Under his leadership, he has focused on advancing innovative therapies while addressing challenges in healthcare costs and access. Narasimhan advocates for sustainable practices in the pharmaceutical industry, emphasizing the need for ethical pricing of medications to ensure that life-saving treatments are accessible to all patients.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Switzerland | 2 | 6.00 | 0.18% | +10% | 8,654,622 | 17,092 | $700,000 | 1,382$ |
| Totals | 2 | 8,654,622 | 17,092 | $700,000 | 1,382$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Switzerland:
Vas Narasimhan, the CEO of Novartis, tempered high expectations from the White House regarding job creation.
5
Switzerland:
Vas Narasimhan is the CEO of Novartis and assured that the negotiations with the American government are going well.
7
Switzerland:
Vas Narasimhan, the CEO of Novartis, has stated that the medication prices in Switzerland are much too low.
5
Slovenia:
Vas Narasimhan is the CEO of Novartis and is leading the company's acquisition of Avidity Biosciences.
7
Switzerland:
Vas Narasimhan is the CEO of Novartis and commented on discussions with the US government regarding price reductions.
5
Spain:
Vas Narasimhan stated that they are trying to avoid situations where they have to completely withdraw a product from the market.
6
Switzerland:
Vas Narasimhan, CEO of Novartis, mentioned that prices in Switzerland are 'much too low'.
5
Switzerland:
Vas Narasimhan, CEO of Novartis, stated that they aim to minimize the price difference between the US and other industrialized countries.
6
Switzerland:
Vas Narasimhan, CEO of Novartis, stated that drug prices in Switzerland are 'much too low'.
4
Switzerland:
Vas Narasimhan is the CEO of Novartis and has expressed ambivalence about his acceptance in Switzerland.
5